Clinical trialNCT01756729TerminatedPhase 4Interventional

Post-approval Study of NovoTTF-100A in Recurrent GBM Patients

SponsorNovoCure Ltd.Enrollment13Recurrent Glioblastoma Multiforme

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a non-randomized, concurrent control study, designed to confirm that the efficacy of the NovoTTF-100A System in patients with recurrent GBM treated in a real life settings following approval is comparable to that of BSC chemotherapy patients. The device is a portable, battery operated device that was approved for the treatment of adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically- or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Herbert Engelhard, MD, PhD
University of Illinois at Chicago
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Barrow Neurology Clinics
Phoenix, Arizona, United States
University of California San Diego Moores Cancer Center
La Jolla, California, United States
Keck Medical Center of Usc
Los Angeles, California, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
University of Illinois at Chicago
Chicago, Illinois, United States
University of Kentucky, Markey Cancer Center
Lexington, Kentucky, United States
Walter Reed National Military Medical Center
Bethesda, Maryland, United States
Washington University School of Medicine, Division of Oncology
St Louis, Missouri, United States
the Long Island Brain Tumor Center
Lake Success, New York, United States
Geisinger Health System
Danville, Pennsylvania, United States
Baylor Research Institute
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2012
Primary completion: 31 Jan 2018
Completion: 31 Jan 2018
Last update posted: 2 Mar 2016
Registered enrollment: 13
Registry id: NCT01756729

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.